22 Result(s)

Article

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

It is unknown, why only a minority of chronic myeloid leukemia (CML) patients sustains treatment free remission (TFR) after discontinuation of tyrosine kinase inhibitor (TKI) therapy in deep molecular remissio...

C Schütz, S Inselmann, S Sausslele, C T Dietz, M C Müller, E Eigendorff… in Leukemia (2017)

Article

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

The optimal timing of allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) is controversial. We report on 1179 patients with a median age of 48 years who were randomized upf...

J Schetelig, M Schaich, K Schäfer-Eckart, M Hänel, W E Aulitzky, H Einsele… in Leukemia (2015)

Article

Respiratory failure in patients undergoing allogeneic hematopoietic SCT—a randomized trial on early non-invasive ventilation based on standard care hematology wards

The prognosis of patients suffering from respiratory failure (RF) after allogeneic hematopoietic SCT (HSCT) is poor. However, early treatment for using non-invasive ventilation (NIV) may be of benefit. We cond...

M Wermke, S Schiemanck, G Höffken, G Ehninger, M Bornhäuser… in Bone Marrow Transplantation (2012)

Article

The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia

Loss of p53—a tumor suppressor gene located on the short arm of chromosome 17 (band 17p13.1)—was detected in 105 out of 2272 (5%) adult acute myeloid leukemia (AML) patients who took part in the Study Alliance Le...

H Seifert, B Mohr, C Thiede, U Oelschlägel, U Schäkel, T Illmer, S Soucek… in Leukemia (2009)

Article

Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia

F A Fierro, S Brenner, U Oelschlaegel, A Jacobi, H Knoth, G Ehninger, T Illmer… in Leukemia (2009)

Article

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

Mesenchymal stem cells have been shown to mediate immunomodulatory effects. They have been used in patients with steroid-refractory acute GVHD (aGVHD), but their relevance as a therapeutic agent targeting aGVH...

M von Bonin, F Stölzel, A Goedecke, K Richter, N Wuschek… in Bone Marrow Transplantation (2009)

Article

Cyclic severe elevated procalcitonin serum levels in a patient with post polycythemic myelofibrosis carrying a V617F-JAK2 mutation

F. Stölzel, J. Babatz, C. Thiede, G. Siegert, T. Illmer… in Annals of Hematology (2008)

Article

AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity

Neurotoxicity of cytarabine (AraC) is believed to be related to renal insufficiency. We examined the plasma pharmacokinetics of AraC and its deamination product uracil arabinoside (AraU) in four patients with ...

L. H. Lindner, H. Ostermann, W. Hiddemann, A. Kiani… in International Journal of Hematology (2008)

Article

Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation

As low trough levels of mycophenolic acid (MPA) have been measured in recipients of allo-SCTs, we performed a pilot study targeting mycophenolate mofetil (MMF) doses according to the MPA area under the concent...

I Haentzschel, J Freiberg-Richter, U Platzbecker, A Kiani… in Bone Marrow Transplantation (2008)

Article

F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan

Fludarabine is commonly used in combination with busulfan as part of conditioning regimens before allogeneic stem cell transplantation. So far, no data are available on busulfan–fludarabine drug interactions i...

M Bonin, S Pursche, T Bergeman, T Leopold, T Illmer… in Bone Marrow Transplantation (2007)

Article

Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multlineage dysplasia

U Platzbecker, U Germing, U Schäkel, T Illmer, S Soucek, M Schaich, G Ehninger… in Leukemia (2006)

Article

Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34⁺ selected allogeneic hematopoietic cell transplantation

M Bornhauser, C Thiede, J Babatz, J Schetelig, T Illmer, A Kiani, U Platzbecker… in Leukemia (2006)

Article

Rapid and sensitive ty** of NPM1 mutations using LNA-mediated PCR clam**

C Thiede, E Creutzig, T Illmer, M Schaich, V Heise, G Ehninger, O Landt in Leukemia (2006)

Article

Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia

There is substantial need to improve the outcome of patients with high-risk acute myeloid leukemia (AML). The clinical trial reported here investigated a new approach of up-front allogeneic hematopoietic stem ...

U Platzbecker, C Thiede, M Füssel, G Geissler, T Illmer, B Mohr, M Hänel… in Leukemia (2006)

Article

Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission

A total of 22 patients with acute myeloid leukemia (AML) in first complete remission receiving autologous blood stem cell transplantation (ABSCT) were investigated in order to determine factors affecting outco...

D Strodtbeck, M Bornhäuser, M Hänel, L Lerche, M Schaich… in Bone Marrow Transplantation (2005)

Article

Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133⁺ selected hematopoietic stem cells

M Bornhäuser, L Eger, U Oelschlaegel, S Auffermann-Gretzinger, A Kiani… in Leukemia (2005)

Article

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Imatinib (Glivec^®, STI571) is an intracellular acting drug that demonstrates high activity against BCR-ABL-positive chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL). However, many patients...

T Illmer, M Schaich, U Platzbecker, J Freiberg-Richter, U Oelschlägel… in Leukemia (2004)

Article

Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation

Imatinib is a new promising therapeutic option for chronic myeloid leukemia (CML) with efficacy even in the blast phase of the disease. However, most patients treated with imatinib in the blast phase develop p...

M. Schaich, K. Schäkel, T. Illmer, G. Ehninger, M. Bornhäuser in Annals of Hematology (2003)